Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Stindt

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Advance for Nps & Pas|June 26, 2013
Chemotherapy-Induced mucositisDiana Stindt, M Jay Brown
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancerGary G Schwartz, M Craig Hall, Diana Stindt, et al.
Cancer|August 5, 2006
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancerLester S Borden, Peter E Clark, James Lovato, et al.
Urology|June 9, 2004
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinomaPeter E Clark, M Craig Hall, Antonius Miller, et al.
Urology|June 13, 2006
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapyPeter E Clark, M Craig Hall, Lester S Borden, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Advance for Nps & Pas|June 26, 2013
Chemotherapy-Induced mucositisDiana Stindt, M Jay Brown
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancerGary G Schwartz, M Craig Hall, Diana Stindt, et al.
Cancer|August 5, 2006
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancerLester S Borden, Peter E Clark, James Lovato, et al.
Urology|June 9, 2004
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinomaPeter E Clark, M Craig Hall, Antonius Miller, et al.
Urology|June 13, 2006
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapyPeter E Clark, M Craig Hall, Lester S Borden, et al.
Pageof 1